肿瘤药学
腫瘤藥學
종류약학
ANTI-TUMOR PHARMACY
2014年
3期
172-175
,共4页
谢平丽%赵艳洁%李跃辉%王宇环%罗晓玲%李官成
謝平麗%趙豔潔%李躍輝%王宇環%囉曉玲%李官成
사평려%조염길%리약휘%왕우배%라효령%리관성
GP73%原核表达%重组蛋白GP73
GP73%原覈錶達%重組蛋白GP73
GP73%원핵표체%중조단백GP73
GP73%Prokaryotic expression%Recombinant protein GP73
目的:原核表达并纯化高尔基体糖蛋白-73(GolgiProtein73,GP73)。方法以人肝癌细胞系HepG2总RNA为模板,经RT-PCR扩增GP73基因,克隆至原核表达载体pET-21a(+)-TRX中,转化大肠杆菌BL21(DE3),IPTG诱导表达。His-tag磁珠纯化重组蛋白GP73,SDS-PAGE鉴定。结果克隆目的基因的序列正确,未发生碱基突变;重组表达质粒pET21a(+)-TRX-GP73经双酶切鉴定构建正确;表达的重组蛋白相对分子量为80 kD,与预期相符。结论本实验成功在大肠杆菌BL21(DE3)中表达并纯化了GP73重组蛋白,为后续研究奠定了基础。
目的:原覈錶達併純化高爾基體糖蛋白-73(GolgiProtein73,GP73)。方法以人肝癌細胞繫HepG2總RNA為模闆,經RT-PCR擴增GP73基因,剋隆至原覈錶達載體pET-21a(+)-TRX中,轉化大腸桿菌BL21(DE3),IPTG誘導錶達。His-tag磁珠純化重組蛋白GP73,SDS-PAGE鑒定。結果剋隆目的基因的序列正確,未髮生堿基突變;重組錶達質粒pET21a(+)-TRX-GP73經雙酶切鑒定構建正確;錶達的重組蛋白相對分子量為80 kD,與預期相符。結論本實驗成功在大腸桿菌BL21(DE3)中錶達併純化瞭GP73重組蛋白,為後續研究奠定瞭基礎。
목적:원핵표체병순화고이기체당단백-73(GolgiProtein73,GP73)。방법이인간암세포계HepG2총RNA위모판,경RT-PCR확증GP73기인,극륭지원핵표체재체pET-21a(+)-TRX중,전화대장간균BL21(DE3),IPTG유도표체。His-tag자주순화중조단백GP73,SDS-PAGE감정。결과극륭목적기인적서렬정학,미발생감기돌변;중조표체질립pET21a(+)-TRX-GP73경쌍매절감정구건정학;표체적중조단백상대분자량위80 kD,여예기상부。결론본실험성공재대장간균BL21(DE3)중표체병순화료GP73중조단백,위후속연구전정료기출。
Objective To prokaryotically express and purify Golgi protein 73(GP73). Methods We amplified GP73 gene from human hepatoma cell HepG2 by RT-PCR and cloned it into the prokaryotic expression vector pET21a(+)-TRX, then transformed it into Escherichia coli BL21 (DE3). The expression of GP73 protein was induced by isopropylβ-D-1-thiogalactopyranoside (IPTG) and purified by His-tag magnetic beads. SDS-PAGE was used to identify GP73. Results Gene GP73 was cloned from HepG2 without any mutation. The recombinant plasmid pET21a(+)-TRX-GP73 was con-structed correctly and the recombinant protein GP73 was expressed successfully with an expected molecular weight of 80KD. Conclusion We successfully expressed and purified the recombinant protein GP73 in Escherichia coli BL21 (DE3) and layed a foundation for following study.